Vitamin B12 Test — Test Guide & Results Explained — Purpose, Procedure & Normal Values | MyMedicPlus

A vitamin B12 test measures the concentration of cobalamin (vitamin B12) in the blood. B12 is an essential water-soluble vitamin that participates in several critical metabolic processes: red blood cell formation and DNA synthesis (deficiency causes megaloblastic anaemia — production of abnormally large, dysfunctional red blood cells); production and maintenance of the myelin sheath surrounding nerve fibres (deficiency leads to progressive, potentially irreversible neurological damage including peripheral neuropathy and subacute combined degeneration of the spinal cord); and homocysteine metabolism (B12 is a cofactor for methionine synthase — deficiency raises plasma homocysteine, an independent cardiovascular risk factor). Vitamin B12 is found exclusively in animal-derived foods (meat, poultry, fish, eggs, dairy products) and fortified foods. It is absorbed in the terminal ileum via a highly specific mechanism involving intrinsic factor — a glycoprotein secreted by gastric parietal cells — which binds B12 in the stomach and escorts it to its ileal absorption receptor (cubilin). Body stores of B12 (predominantly in the liver, totalling 2–5 mg) can last 3–5 years, meaning deficiency develops slowly and insidiously, often presenting without obvious dietary explanation.

A vitamin B12 test is ordered when a full blood count (CBC) reveals macrocytic anaemia — characterised by large red blood cells with an elevated mean corpuscular volume (MCV above 100 fL) — often with hypersegmented neutrophils (five or more lobes in more than 5% of neutrophils) on the blood film. It is ordered to investigate symptoms of B12 deficiency including persistent fatigue, generalised weakness, pallor, exertional breathlessness, glossitis (a sore, smooth, inflamed tongue with loss of papillae), and neurological symptoms including tingling and numbness in a glove-and-stocking distribution (peripheral neuropathy), difficulty walking, loss of proprioception and vibration sense, spasticity, and cognitive impairment or depression. B12 testing is essential in the diagnostic workup of subacute combined degeneration of the spinal cord (SACD) — a potentially irreversible posterior and lateral column myelopathy. At-risk groups who require routine B12 monitoring include: vegans and strict vegetarians (no dietary B12 source without supplementation or fortified foods); elderly people over 65 (reduced gastric acid secretion impairs B12 release from food proteins, and intrinsic factor output may decline); patients with pernicious anaemia (autoimmune destruction of parietal cells — the most common cause of B12 deficiency in developed countries); patients on long-term metformin (impairs ileal B12-intrinsic factor complex uptake); those on proton pump inhibitors (PPIs) long-term; and patients after gastrectomy, bariatric surgery, or with Crohn's disease affecting the terminal ileum.

Fasting for 6–8 hours before the blood draw is preferred, as a recent high-animal-protein meal can transiently elevate serum B12 levels by releasing B12 from dietary sources into circulation, potentially masking borderline deficiency in patients with a low-normal result. Plain water and essential medications with a small amount of water are allowed during the fasting period. Inform your doctor or the laboratory if you are currently taking vitamin B12 supplements — either oral cyanocobalamin or hydroxocobalamin — or a multivitamin containing B12. High-dose or recent B12 supplementation can produce a misleadingly normal or even elevated serum B12 reading in a patient who has genuine cellular B12 deficiency (functional deficiency), because the serum measures total B12 — both active and inactive forms — not B12 at the tissue level. If your doctor has ordered additional functional B12 markers such as methylmalonic acid (MMA) or holotranscobalamin (active B12), these should ideally be measured from the same fasting sample. Note the timing and dose of your last B12 supplement for the requesting clinician.

A phlebotomist draws 3–5 mL of venous blood from the antecubital fossa of the arm using standard venepuncture technique. The blood is collected into a serum separator tube (gold-top), which is allowed to clot for 15–20 minutes before centrifugation separates the serum. The serum is analysed on an automated immunoassay platform using competitive binding chemiluminescent or electrochemiluminescent immunoassay, measuring total serum cobalamin (B12) concentration in pg/mL or pmol/L. Serum B12 measures total circulating cobalamin but does not distinguish between its two main bound forms: holotranscobalamin (holoTC, or active B12 — bound to transcobalamin II, the fraction taken up by cells and metabolically active, approximately 20% of total serum B12) and haptocorrin-bound B12 (biologically inactive, approximately 80% of total serum B12). When clinical suspicion of B12 deficiency is high despite a normal or borderline serum B12, the following additional markers provide greater functional sensitivity: holotranscobalamin (active B12, the earliest marker to decline in B12 depletion — deficient below 35–40 pmol/L) and serum methylmalonic acid (MMA — elevated above 0.40 mcmol/L when B12 is functionally insufficient at the cellular level — the most sensitive and specific indicator). Results for serum B12 are typically available within 24 hours.

Normal serum vitamin B12 reference range: 200–900 pg/mL (148–664 pmol/L) — ranges vary slightly between laboratories and assay platforms. Result interpretation: Frank deficiency: below 200 pg/mL (148 pmol/L) — neurological and haematological complications are probable and require urgent investigation and treatment; Borderline or grey zone: 200–300 pg/mL (148–221 pmol/L) — functional deficiency may exist even with serum levels in this range; MMA and homocysteine should be measured to detect cellular deficiency in this group; Normal: 300–900 pg/mL; Elevated: above 900 pg/mL — may indicate liver disease (hepatic B12 release), myeloproliferative disorders (polycythaemia vera, chronic myeloid leukaemia — from elevated haptocorrin), solid organ tumours, or excess supplementation. Supplementary markers: elevated MMA (above 0.40 mcmol/L) with low-normal serum B12 confirms functional cellular B12 deficiency; elevated plasma homocysteine (above 15 mcmol/L) also occurs in B12 and folate deficiency; decreased holotranscobalamin (holoTC) below 35 pmol/L is the earliest and most specific indicator of cellular B12 depletion.

The blood draw carries minimal clinical risk — minor bruising or haematoma at the venepuncture site is the most common, and brief vasovagal reactions (dizziness, faintness) are uncommon. The most significant clinical limitation of the serum B12 test is that it is a total measurement — it combines both active holotranscobalamin and inactive haptocorrin-bound B12 — and does not directly reflect intracellular B12 status. Approximately 40–50% of patients with early functional B12 deficiency (insufficient cellular B12 despite adequate-seeming serum levels) have serum B12 results in the normal range, because high levels of inactive haptocorrin-bound B12 mask the deficiency of the bioavailable fraction. This is particularly important in patients with liver disease, myeloproliferative conditions, or SIBO (small intestinal bacterial overgrowth — where bacteria produce excess inactive B12 analogues that elevate serum B12 without having any nutritional benefit). Conversely, falsely low serum B12 can occur in pregnancy (haemodilution and increased maternal B12 transfer to the fetus lower maternal serum levels), in patients with folate deficiency, or with certain medications. For these reasons, clinical interpretation of borderline serum B12 must consider the full clinical picture, the MMA level, and the holotranscobalamin result rather than serum B12 in isolation.